PubMed Health⌕ Search

Biomedical subjects

S Ohtake

Publications and source records attributed to S Ohtake.

At least 181 records · Page 10Linked to original sources
PubMed1984

[Phase II study of etoposide (NK 171) in advanced hematological malignancies].

A clinical study of a new semisynthetic podophyllotoxin etoposide (NK 171) was performed in patients with various hematological malignancies refractory to standard chemotherapies. The drug was given intravenously in a dose of 100-130 mg/m2/day for five days or orally in a dose of 130-170 mg/m2/day for five days. Out of 9 patients with non-Hodgkin's lymphoma, 2 CR and 4 PR were obtained; out of 4 acute nonlymphoblastic leukemias, 1 CR, and out of 4 chronic myerogenous leukemias 2 CR and 1 PR, were obtained. The dose limiting factor was leukopenia, and alopecia was frequent while other hematologic and gastrointestinal toxicities were mild. Etoposide (NK 171) had no clinical cross resistance to other antitumor agents, thus warranting further clinical trials, in combination chemotherapy against NHL, ANLL and CML-BC.

Administration, Oral↗
PubMed1983

[Autologous bone marrow transplantation in the treatment of nasopharyngeal carcinoma--report of 2 cases].

Two patients with nasopharyngeal carcinoma (NPC) were treated with "marrow-lethal" chemoradiotherapy and infusion of cryopreserved autologous marrow. Patient AUT 04 (unique patient number), a 28-year-old male, was referred to us because of the right cervical lymphadenopathy. He was diagnosed NPC at stage II (T1N2M0). A trial of combined-modality therapy using autologous bone marrow transplantation (auto-BMT) was scheduled for possible cure. Before auto-BMT, he was treated with a conventional dose of radiation to the nasopharyngeal and bilateral cervical areas. For the pretransplant marrow-lethal therapy, he received high-dose cyclophosphamide (CY), 120mg/kg, and 1,000 rad total body irradiation (TBI). Within 24 hr after TBI, previously cryopreserved-thawed autologous bone marrow cells (1.37 X 10(8)/kg) was infused to the patient. Rapid and complete hematologic recovery was observed and he is now alive in a disease-free remission state 28 months after transplantation. Patient AUT 08, a 18-year-old female, was referred to us for the treatment of head and neck tumor with auto-BMT. She was diagnosed NPC at stage IV (T4N2M0). After cryopreservation of bone marrow, she was treated with local radiation and doxorubicin (80mg X 2d). Then she was conditioned with high-dose CY and upper half body irradiation and received auto-BMT (marrow dose: 1.2 X 10(7)/kg). Successful engraftment was obtained with tumor response but she developed recurrence of the disease 12 months after transplantation. Although the data are too preliminary, auto-BMT is evaluated as one of the favorable treatment approaches for some selected patients with NPC.

Adolescent↗
PubMed1983

Hematologic recovery following autologous and allogeneic bone marrow transplantation.

Posttransplant hematologic recovery was compared between 9 autologous and 11 allogeneic marrow transplant patients who received similar marrow-lethal chemoradiotherapies before transplantation. Although the autotransplant patients were infused with much lower marrow doses compared with the allotransplant patients, they showed adequate hematologic recovery with acceptable risk. Regardless of marrow doses, delayed platelet recovery and failure of platelet recovery were observed in 7 patients. All of these patients experienced early transplantation-related complications before engraftment. Despite the limited number of patients, a number of myeloid progenitor cells (CFUC) infused correlated significantly with the period for recovery of polymorphonuclear cells in autologous marrow recipients while there was no significant correlation found between marrow dose and hematologic recovery in both groups of patients. Furthermore, autotransplant patients showed a characteristic recovery pattern of peripheral blood lymphocytes in an early posttransplant period, whic was not observed in allotransplant patients.

Acute Disease↗